TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06971094: A Multicenter, Randomized, Open-Label, Standard-of-Care-Controlled, Phase III Clinical Trial to Evaluate the Safety and Efficacy of Intrathecal (IT) Injection of GC101 Adeno-Associated Virus Injection in the Treatment of

Sponsor: GeneCradle Inc · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 50 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$18,794,410

Rescue Site Savings

+$12,432,100

Unlock Full NCT06971094 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06971094 Rescue Dossier →